Objective: We evaluated the relationship between annually measured serum endogenous estradiol and the development or worsening of stress and urge incontinence symptoms during a period of 8 years in women transitioning through menopause.
T he increasing prevalence of urinary incontinence with aging in women has traditionally been linked to the declining levels of estrogen associated with the men-opausal transition and postmenopause. > and A estrogen receptors exist throughout the urogenital tract, and exogenous estrogen increases urethral cellular maturation, 1 urethral blood flow, 2 and urethral pressure 3<5 presumed to be important to continence. However, secondary analyses of randomized clinical trials have revealed that estrogen treatment in postmenopausal women is associated with a higher risk of newly developing and worsening existing incontinence. 6, 7 Less is known about how endogenous estrogen levels affect incontinence.
In our previous work, we found that advancement through the stages of the menopausal transition was not significantly associated with the development or worsening of incontinence during the first 6 years of the Study of Women's Health Across the Nation (SWAN). 8, 9 However, epidemiological evidence to date suggests a weak negative effect of endogenous estrogen on incontinence. Higher levels of serum estradiol (E 2 ) have been associated with more prevalent incontinence symptoms in a cross-sectional study. 10 A steep decline in serum E 2 levels during a period of 11 years was associated with a decrease in incontinence symptoms compared with a more gradual decline or no change in E 2 levels across the same time frame. 11 Our objective was to evaluate the relationship between annually measured serum endogenous E 2 levels and the development or worsening of self-reported stress and/or urge incontinence symptoms across the menopausal transition in the first 8 years of SWAN. We also investigated the association with other reproductive hormone levels, specifically follicle-stimulating hormone (FSH), testosterone, and dehydroepiandrosterone sulfate (DHEAS). In these analyses, we accounted for other factors known to affect the development or worsening of incontinence such as high body mass index (BMI), weight gain, anxiety, and diabetes.
METHODS

Study sample
SWAN is a multicenter prospective cohort study of women from five racial/ethnic groups who have been followed to characterize the menopausal transition. 12 SWAN comprises seven clinical sites (Boston, MA; Chicago, IL; the Detroit area, MI; Los Angeles, CA; Newark, NJ; Pittsburgh, PA; and Oakland, CA), a coordinating center, and a central endocrine laboratory. The SWAN is a community-based sample of 3,302 women: the white and minority groups do not represent an underlying population distribution. All seven sites recruited white women (n = 1,550 white), and three sites recruited African American women (n = 395). Japanese (n = 281), Chinese (n = 250), and Hispanic (n = 286) women were recruited at one site each. The eligibility criteria for the SWAN cohort were an age of 42 to 52 years and self-identification as one of the five racial/ethnic groups. The exclusion criteria included the inability to speak English, Spanish, Japanese, or Cantonese; no menstrual period in more than 3 months before enrollment; having had a hysterectomy and/or bilateral oophorectomy before enrollment; and current pregnancy or hormone use. The institutional review boards at all sites approved the SWAN protocol, and all women gave informed consent to participate.
Outcome variables
The women included in this analysis were those followed through eight annual follow-up visits (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . The SWAN obtained baseline and annual information on incontinence symptoms, incontinence frequency, and type through a self-administered questionnaire. Based on the response to the question BIn the past year (or since your last study visit), have you ever leaked even a small amount of urine involuntarily? [ Women who were continent at baseline but then reported incontinence at any of the eight annual follow-up visits were considered to have incident incontinence and were compared with women who did not develop incontinence over the same time frame. Women who reported incontinence at any time point and then reported an increase in frequency from 1 year to next were considered to have worsening incontinence, that is, from no regular incontinence (after a previous report of incontinence) to monthly or more, from monthly to weekly or more, or from weekly to daily. We compared women with worsening incontinence with those with no change (same frequency from one visit to the next) or improved (decreased frequency from one visit to the next) incontinence.
Hormones
Our main variable of interest was the annually measured value of E 2 . We also evaluated FSH, testosterone, and DHEAS and the year-to-year changes in the values. SWAN measured these four hormones annually with the goal of standardizing them from year to year by drawing blood in the early follicular phase, days 2 to 5 of the menstrual cycle, whenever possible. We categorized the time of phlebotomy for the hormone assays as follows. For premenopause and early perimenopause, we defined phlebotomy between days 2 to 5 to be Bin window,[ whereas we defined phlebotomy done outside of days 2 to 5 to be Bout of window.[ Because late perimenopause is characterized by long periods of amenorrhea, the number of women whose blood was drawn between days 2 and 5 of a menstrual cycle was too few for analysis. Therefore, we considered phlebotomy in late perimenopause or postmenopause as random annual time points in each of these transition stages.
All endocrine assays were performed on the Automated Chemiluminesence System (ACS)-180 analyzer (Bayer Diagnostics Corporation, Tarrytown, NY) using a doubleantibody chemiluminescent immunoassay with a solid-phase anti-IgG immunoglobulin conjugated to paramagnetic particles, antiligand antibody, and competitive ligand labeled with dimethylacridinium ester. 13 The E 2 assay modified the rabbit anti-E 2 -6 ACS-180 immunoassay to increase sensitivity, with a lower limit of detection of 1.0 pg/mL. Duplicate E 2 assays were conducted with the results reported as the arithmetic mean for each participant, with a coefficient of variation of 3% to 12%. All other assays were single determinations. The FSH assay was a modification of a manual assay kit (Bayer Diagnostics) using two monoclonal antibodies directed to different regions on the A subunit. The testosterone assay modified the rabbit polyclonal antitestosterone ACS-180 immunoassay. The DHEAS and sex hormoneYbinding globulin (SHBG) assays were developed on site using rabbit anti-DHEAS and anti-SHBG antibodies.
Covariates
SWAN classified menopause status from the menstrual bleeding patterns annually. Premenopause was defined by less than 3 months of amenorrhea and no menstrual irregularities in the previous year; early perimenopause was defined by less than 3 months of amenorrhea and some menstrual irregularities in the previous year; late perimenopause was defined by 3 to 11 months of amenorrhea; and postmenopause was defined by 12 consecutive months of amenorrhea. Because we aimed to evaluate the effects of natural menopausal serum hormone levels on incontinence, we permanently censored women who had a hysterectomy with or without bilateral salpingoophorectomy before their final menstrual period (because the menopausal transition stage of these women became unclassifiable). Women who started taking systemic hormones were excluded at the time of hormone initiation (because hormone therapy use before the final menses obscures the classification of menopausal transition stage and also because hormone therapy use precludes the measurement of endogenous sex steroids). However, women who stopped hormones and for whom we could determine the menopause status re-entered our analysis in that status after a washout period of at least 6 months.
We calculated BMI as weight in kilograms divided by the square of height (in meters) based on measurements taken annually by certified staff who used calibrated scales and a stadiometer. As described previously, covariates were measured using mostly validated questions. 8 The socioeconomic status was approximated by level of difficulty paying for basics (food, heat, and shelter) at baseline. The sensitivity to body symptoms was collected at the first annual visit. 14 Each year, the interviewers obtained self-reported medical histories, smoking history, and medication use. In annual self-report questionnaires, SWAN used the same validated questions eliciting depressive symptoms, 15 social support and stressors, 16, 17 and anxiety symptoms. 18 
Missing Data
We defined dropouts as those who were deceased, discontinued the study voluntarily, or could not be contacted after missing two or more annual visits. When a woman was missing data on frequency and type of incontinence from one or two visits, we imputed the values as follows. If the missing value occurred at year 8, we imputed the value at the previous visit. If women reported no incontinence in the years before and after a missing incontinence report, we assumed no incontinence in those missing years. If a woman was missing incontinence data in the 1 to 2 years before the first report of incontinence, then we randomly assigned her missing values to either no incontinence or the frequency and/ or type of incontinence in that subsequent year. We imputed incontinence frequency for 1,018 women at 1,487 visits (7.1% of all visits) and incontinence type for 1,511 women at 2,759 visits (13.2% of all visits). We only imputed one or two missing hormone values when they occurred between two known values measured in the same menopause status. In addition, for premenopause and early perimenopause, we only imputed hormone values between two known values from blood drawn in-window in the same status. In these cases, the missing value or values were randomly assigned the previous or subsequent value. We imputed 2,826 hormone values for 248 women (1.9% of all values). When the weight was missing for one or two visits, the values for 501 women were imputed as the mean between the two known values for 1,379 visits (6.6% of all visits). Similarly, waist circumference values were imputed for 527 women at 1,414 visits (6.8% of all visits). We dropped all other missing data from the analysis.
Data Analyses
We used t, W 2 , and the Kruskal-Wallis tests to compare the distributions of each variable for women at baseline who remained in with those who dropped out of the study by year 8. We used a discrete Cox survival model using timedependent annual hormone values and change in values, adjusting for both time-varying and baseline covariates to model time until the incident incontinence. This model is used to analyze the effects of each unique annual hormone value, or change in value, on the hazard of incontinence, adjusted for potential confounding factors. To evaluate the association between the hormone level or change in level and worsening incontinence, we modeled the marginal probabilities of worsening (at the time of observation compared with improving or no change in incontinence) as logistic regressions using timedependent annual hormone values and change in values and adjusting for both baseline and time-varying covariates. Here, we used the generalized estimating equations (GEEs) methodology, which is designed to accommodate the dependence of repeated observations on the same women.
To evaluate the association between annual hormone value and time to the development of incontinence, we ran two separate models, one using the value of E 2 , FSH, testosterone, and DHEAS in the year of first reported incontinence, and the other in the year before the first report of incontinence in previously continent women. To evaluate the association between worsening incontinence and the time-dependent variables, E 2 , FSH, testosterone, and DHEAS, we again developed two models, one using these hormone values in the year of and the other using them in the year before the reported increase in the frequency of incontinence. We also ran models with each hormone alone and with different combinations of the hormones and found no differences in the point estimates of any model variable. We ran the same models using free E 2 index (total E 2 /SHBG Â 100) and free androgen index (total testosterone/SHBG Â 100) without adjusting for SHBG and found no differences in the results.
We were also interested in whether the annual change in hormone level was associated with the development or worsening of incontinence. We defined change in hormone level as the difference in E 2 , FSH, testosterone, and DHEAS values between the year of and the year before either the first report of incontinence in continent women or the reported increase in frequency of incontinence. In the discrete Cox survival and in the GEE models, we included all late perimenopausal and postmenopausal women and the premenopausal and early perimenopausal women whose hormone values were in window. Dropout cohort: those who were deceased, voluntarily withdrew, or could not be contacted for two or more visits by year 6. c Comparison between follow-up and dropout cohorts using t test and W 2 test.
We excluded out-of-window hormone values because the meaning of annual change between out-of-window hormone values in women who still have some regular menstrual cycles is not interpretable.
Candidate covariates for all our models included factors found to be associated with incontinence in the literature or in our previous analyses, possible confounders of the relationship between hormone level and incontinence based on a priori hypotheses, and those associated with our incontinence outcomes with P G 0.10. Besides the hormone values and change in values, time-varying covariates included menopause status/ phlebotomy window, weight change, the occurrence of stressful life events, the development of anxiety and depressive symptoms, social support, and general health status. We checked the proportional hazard assumptions for our baseline covariates (race/ethnicity, education level, marital status, difficulty paying for basics, baseline BMI, baseline smoking, parity, baseline diabetes, baseline hypertension, and baseline fibroids) using our previously described methods. 8, 9 To evaluate the effects of our imputation methods, we ran both types of models with and without imputed hormone and other variable values and found no appreciable differences in the model results. For all analyses, we used SAS 9.1 (SAS Institute Inc., Cary, NC).
RESULTS
The baseline characteristics of women who were followed up for all 8 years were different than those of the women who dropped out of the study ( Table 1 ). The 2,891 women who stayed in the study were more likely to have a higher education, have better health, be married, have an easier time paying for basics, have never smoked, be white, have a lower anxiety score, have higher levels of DHEAS and SHBG and lower levels of FSH, and have incontinence compared with the 407 women who dropped out. Although these differences may limit the generalizability of this study, the small magnitude of the differences is unlikely to affect the biological relationship between endogenous hormone levels and incontinence.
During the 8 years of the study, 738 women in the followup cohort were censored because of starting hormones in premenopause or perimenopause, but 70% re-entered the study after stopping hormones and resuming a natural menstrual cycle for at least 1 year. Ninety-six women were censored after having a hysterectomy with or without oophorectomy before their final menstrual period. Overall, 1,587 of 2,891 (55%) women transitioned to natural postmenopause.
We found that annual serum reproductive hormone levels measured in women transitioning through menopause were FIG. 1. A: Mean estradiol and FSH levels in women who developed and did not develop UI across the natural menopausal transition. Number of observations in each year: j6, 365; j5, 481; j4, 522; j3, 556; j2, 557; j1, 513; 0, 442; +1, 327; +2, 245; +3, 164; +4, 109; +5, 60; +6, 24. B: Mean estradiol and FSH in women whose UI did and did not worsen across the natural menopausal transition. Number of observations in each year: j6, 59; j5, 117; j4, 183; j3, 237; j2, 286; j1, 336; 0, 368; +1, 320; +2, 253; +3, 177; +4, 105; +5, 54; +6, 25. FSH, follicle-stimulating hormone; UI, urinary incontinence. not associated with the development or worsening of incontinence. The mean E 2 and FSH levels, which change considerably across the menopausal transition, did not differ between those who developed and those who did not develop incontinence (Fig. 1A) . Similarly, these hormone levels did not differ between incontinent women who reported worsening incontinence compared with those who did not have worsening incontinence (Fig. 1B) .
In our proportional hazards models, the E 2 , FSH, DHEAS, and testosterone levels drawn at either the annual visit concurrent with or before each woman's first report of incontinence were not associated with the development of any, stress, or urge incontinence in previously continent women (Table 2) . Similarly, in our GEE models, the hormone levels drawn in concurrent and previous years were not associated with the worsening of any incontinence in incontinent women The comparison group is composed of all women who did not develop stress incontinence. All hormones are in model and are adjusted for the following timevarying covariates: serum hormoneYbinding globulin, menopause status/window of phlebotomy, weight gain, and the following baseline covariates: parity, race/ ethnicity, and baseline body mass index.
c The comparison group is composed of all women who did not develop urge incontinence. All hormones are in model and are adjusted for the following timevarying covariates: serum hormoneYbinding globulin, menopause status/window of phlebotomy, weight gain, change in life events, change in anxiety score, and the following baseline covariates: baseline body mass index, baseline hypertension, parity, race/ethnicity, baseline educational level, and baseline level of difficulty paying for basics. The comparison group is composed of all women whose incontinence improved or did not change. All hormones are in both models and are adjusted for the following time-varying covariates: serum hormoneYbinding globulin, menopause status/window of phlebotomy, weight gain, waist gain, change in social support, change in life events, current anxiety, current depression symptoms, and the following baseline covariates: marital status, parity, smoking status, symptom sensitivity score, baseline age, baseline body mass index, baseline hypertension, baseline education, baseline diabetes, baseline difficulty paying for basics, race/ethnicity, baseline health status, fibroids at baseline, and first reported frequency of incontinence. FSH, follicle-stimulating hormone; DHEAS, dehydroepiandosterone sulfate; OR, odds ratio.
( Table 3 ). The odds ratios for stress and urge incontinence were also close to 1.00, whereas the 95% CI was 0.99 to 1.01.
Finally, in our models examining the change in E 2 , FSH, DHEAS, and testosterone levels from the previous to the concurrent year of first report or increased frequency of incontinence, we again found no association between annual change in these hormone levels and the development or worsening of incontinence. As with our other analyses, the hazard and odds ratios calculated were between 0.98 (95% CI, 0.97<1.00) and 1.03 (95% CI, 0.99<1.05).
DISCUSSION
We found that the annually measured values and year-toyear changes in endogenous serum E 2 levels had no significant relation to the development or worsening of urinary incontinence in midlife women transitioning through menopause. These findings have at least two possible biological explanations. First, endogenous estrogens are not related to the development or worsening of incontinence. Second, and more probably based on previous work, 10,11 endogenous estrogens have at least a weak association with incontinence, but this relationship is not based on annual values or betweenyear changes in isolated serum E 2 levels but rather is hidden within the complexity of estrogen action at the level of the urogenital and/or neural tissues. For example, > and A estrogen receptor distribution and density can vary in different tissues depending on estrogen exposure 19 and menopause status. 20 Genotypic variation in estrogen receptors and in estrogen metabolism may lead to the different effects of estrogen on incontinence as a unique estrogen receptor, and estrogen metabolic pathway single nucleotide polymorphisms have been associated with different health measures such as bone mineral density and symptoms such as depression and hot flushes. 21<23 We also found no association between FSH, testosterone, or DHEAS levels and the development or worsening of incontinence. Few studies have evaluated the relationship of these hormones with incontinence. In spayed female dogs, lower FSH concentrations were associated with incontinence adjusting for body weight and time from spaying. 24 We could identify no studies evaluating FSH and incontinence in humans, but no direct biological action of FSH on the urogenital tissues has been identified that could explain a relationship. Although androgen receptors are present in the levator ani muscles, their numbers are small compared with estrogen receptors. 25 Women with stress incontinence have been reported to have higher levels of urine androgen metabolites compared with continent women, 26 and higher serum testosterone levels have been associated with reduced collagen turnover in the urogenital tissues of stress incontinent compared with continent women, 27 suggesting that, biologically, androgens may have a protective effect against the development or worsening of stress incontinence. However, our results support the current evidence of no simple epidemiological association between testosterone and/or androstendione and incontinence. 10 One main limitation of our study was that E 2 , FSH, DHEAS, testosterone, and SHBG levels were measured just once per year. In most cases, these were measured in days 2 to 5, the early follicular phase of the menstrual cycle, but in perimenopausal women especially, the cycles may vary significantly; therefore, a single measurement may not be representative of the other cycles during that year. In addition, one of our main outcomes, worsening incontinence, was based on self-reported incontinence frequency that may not always represent a true biological change in incontinence but rather may represent a change in reporting behavior associated with a change in other factors such as anxiety symptoms. Exactly when incontinence developed or worsened in the previous year was not certain and thus cannot be directly linked with a specific hormone measurement.
SWAN has followed almost 2,900 community-based women of diverse race/ethnicity during the menopausal transition for more than 8 years using standardized questionnaires and annual blood draws for sensitive E 2 and other reproductive hormone assays. The same incontinence questions assessing the clinical type of incontinence (stress and urge) were asked on an annual basis. These questions were similar to validated questions and those that have been used widely in other epidemiological studies of incontinence. 28, 29 The sensitivity and specificity of self-reported stress and urge incontinence are estimated to be 71% to 85% and 60% to 79%, respectively, in validated questionnaires. 30, 31 CONCLUSIONS These negative findings add a small piece to the puzzle of the relationship between estrogen and urinary incontinence. From a clinical standpoint, our findings challenge previously held beliefs about low or declining levels of estrogen being associated with incontinence. Rather, levels of and changes in E 2 (or any of the other reproductive hormones examined here) have no measurable relation to the development or worsening of incontinence over time. However, because of the evidence that exogenous estrogen affects symptoms of incontinence negatively and because the action of estrogen is complex, future studies should explore whether incontinence may be associated with other facets of this complexity, such as genetic variation in estrogen metabolism and receptor expression.
